At the end of treatment (Day 56), R23FR/Ifng-/- mice had much less severe colitis than R23FR/Ifng+/+ mice, as measured by histology and elevation of fecal lipocalin (Fig. 8B–D). This evidence concerns the gene IFNG and colitis.